Form 4: Director Darren S. Cline Receives Pliant Therapeutics Grant

Director Darren S. Cline was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of a standard equity compensation package.

Summary

• Director Darren S. Cline acquired 70,000 stock options in Pliant Therapeutics, Inc. (PLRX).
• The options have an exercise price of $1.14 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on the director's continued service to the issuer to satisfy vesting requirements.

Future Outlook

The options vest in installments starting October 1, 2026, through the one-year anniversary of the grant or the next annual meeting, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized to drive long-term clinical and commercial success.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for mid-cap biotechnology firms.
• The use of time-based vesting is a common industry practice to ensure director retention.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 25% of options on October 1, 2026.
• Vesting of 25% of options on January 1, 2027.
• Vesting of 25% of options on April 1, 2027.
• Final vesting of remaining 25% on the earlier of June 11, 2027, or the next annual meeting.

Key Dates

Keywords

PLRX, Pliant Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation